Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Date:3/20/2012

share, compared with a net loss of $14.3 million, or $21.84 per share, for the same period in 2010.  Common shares used in calculating basic and diluted earnings per share were 17,345,000 for the year ended December 31, 2011 compared to 657,000 common shares for the year ended December 31, 2010.

As of December 31, 2011, AcelRx had cash, cash equivalents and investments of $35.8 million, compared to $32.0 million at September 30, 2011 and $3.7 million at December 31, 2010.  In February 2011, AcelRx completed its initial public offering, resulting in net proceeds to AcelRx of $34.9 million.  In June 2011, AcelRx entered into a $20.0 million secured loan agreement with Hercules Technology Growth Capital, or Hercules.  Upon execution of the agreement, AcelRx received $10.0 million in the first tranche of the loan and, in December 2011, AcelRx drew down the second $10.0 million tranche of the loan.

"During the last quarter of 2011 and into the first quarter of 2012, AcelRx completed system verification testing, software validation testing and reprocessing validation testing of our ARX-01 device, in addition to filing a new IND for our ARX-04 product candidate.  In early March 2012, AcelRx accomplished a major milestone with the initiation of our first Phase 3 efficacy and safety study for ARX-01 for the treatment of post-operative pain following open abdominal surgery. Shortly, we will be initiating the second Phase 3 study, an active comparator study comparing ARX-01 to the standard of care. These studies, along with the third and final Phase 3 study to support an NDA for ARX-01 due to start in the second half of this year, will set up a very exciting 2012 with data from all three studies expected by early 2013," said Richard King, President and CEO of AcelRx.

Development Update

  • In early March 2012, AcelRx initiated the first of three planned ARX-01 Phase 3 studies. This study is a randomized, double-blind, p
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
    2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
    3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
    4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
    5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
    6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
    7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
    8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
    11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
    (Date:3/27/2015)... 27, 2015 The International Myeloma Foundation (IMF) ... while working toward prevention and a cure – today ... a federal resolution (H. Res. 174) that supports the ... Multiple Myeloma Awareness Month." Currently there are ... more than 110,000 new cases are diagnosed yearly, according ...
    (Date:3/27/2015)... DALLAS , March 27, 2015 ... Review, H1 2015" therapeutic market research report of ... to its online business intelligence library. ... comprehensive information on the therapeutic development for Visceral ... therapeutics assessment by drug target, mechanism of action ...
    Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
    ... 2012  Michael Volkov has joined the law firm of ... will be resident in the firm,s Alexandria, Va. and ... and veteran white collar defense attorney will provide compliance, ... broad range of issues, including the Foreign Corrupt Practices ...
    ... today that their applications for Transvaginal Mesh cases and ... company began funding plaintiffs for Mesh cash advances beginning ... industry do not fund Vaginal Mesh or Hernia Mesh ... is one of the few companies now offering plaintiffs ...
    Cached Medicine Technology:Veteran FCPA and White Collar Attorney Michael Volkov Joins LeClairRyan 2Vaginal Mesh and Kugel Hernia Mesh Case Applications for Lawsuit Funding on the Rise at Legal-Bay Settlement Funding 2
    (Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
    (Date:3/27/2015)... (PRWEB) March 27, 2015 DrugDev announced ... (Liss) Easy was named to the 2015 Philadelphia Business ... 40 list spotlights 40 dynamic, up-and-coming leaders less than ... community involvement. Winners are honored at an awards program ... the Philadelphia Business Journal. , Lyn Kremer, Publisher of ...
    (Date:3/27/2015)... USA (PRWEB) March 27, 2015 According ... rates of newborns born with Neonatal Abstinence Syndrome (NAS) ... NAS will undergo the painful withdrawal process for a ... body tremors, excessive crying, diarrhea, and vomiting. The condition ... undergoing drug and alcohol addiction treatment (and employing medically ...
    (Date:3/27/2015)... California’s ongoing worst ever drought, and ... the United States Northeast, are both manifestations of the ... is creating changes in the atmosphere’s “energy balance,” according ... NASA researcher, speaking on the Sharon Kleyne Hour™ Power ... a warmer and dryer global climate but also greater ...
    (Date:3/27/2015)... To address their number one lawn care question ... filming this video to explain the complicated dynamics between the ... often expected to thrive in, be it in dense building ... survive. Anytime a sun-loving plant is put in the shade ... homeowners try to amend this issue by applying large quantities ...
    Breaking Medicine News(10 mins):Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:For Spring Turf Planting Season, Super-Sod Created a New How-To Video Entitled "Two Views on Shade and Turf" 2
    ... Va. The National Institute of Dental and Craniofacial ... (AADR) a multi-year Bloc Travel Grant in the amount ... Each year, this award will assist approximately 50 students ... Dental Research (IADR) General Session & Exhibition for the ...
    ... With the nation,s economic crisis contributing to greater workplace ... be more important than ever. , Unfortunately, the approach ... is flawed and unlikely to produce the best outcomes ... according to a Florida State University College of Medicine ...
    ... "Despite our concerns about the ill-advised proposal to ... by the VA for service-connected health conditions, Vietnam ... President Obama for its generosity in assisting all ... President John Rowan. "VVA joins fellow veterans, service ...
    ... IRVINE, Calif., March 17 Frost & Sullivan ... in the Global Diabetes Diagnostics Market to Epinex for ... . Frost & Sullivan is an internationally renowned market ... years of history in the global marketplace. The ...
    ... March 17 Shands HealthCare has selected the ... key component of its ongoing effort to improve ... healthcare system affiliated with the University of ... in Gainesville and Jacksonville. It includes eight Shands ...
    ... largest water efficiency conference Oct. 7-9 in Las Vegas , ... Denver ... water resources, the American Water Works Association (AWWA), the authoritative ... WaterSmart Innovations Conference and Exposition , Oct. 7-9, 2009, in Las Vegas., ...
    Cached Medicine News:Health News:Researcher wins $2.6 million grant for depression care study 2Health News:Researcher wins $2.6 million grant for depression care study 3Health News:VVA Praises President's Budget Submission for Veterans Affairs; Condemns Ill-advised Revenue Proposal 2Health News:Frost and Sullivan Picks Epinex for Diabetes Research Award 2Health News:Shands HealthCare Selects Micromedex CareNotes System from Thomson Reuters to Improve Patient Education 2Health News:Shands HealthCare Selects Micromedex CareNotes System from Thomson Reuters to Improve Patient Education 3Health News:AWWA partners with WaterSmart Innovations conference 2
    Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
    Bipolar forceps...
    ... INFORM HPV allows the pathologist to visualize the ... allows testing on a choice of sample types: ... HPV cocktails utilize proprietary probe formulations. The Family ... genotypes 16, 18, 31, 33, 35, 39, 51, ...
    ... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
    Medicine Products: